CircuLite® to Present Chronic Hemodynamic Data for
Synergy® Micro-Pump for Chronic Heart Failure at American College Of Cardiology
Annual Scientific Session
Company to Participate in ACC Late-Breaking Session and Mechanical Support
Symposium
SADDLE BROOK, N.J. (March 20, 2009) – CircuLite®, Inc. today announced that
Daniel Burkhoff, M.D., Ph.D., CircuLite’s Chief Medical Officer and Adjunct
Associate Professor of Medicine at Columbia University Medical School, will
present an abstract detailing long-term hemodynamic data on the Synergy® Pocket
Micro-pump in a late-breaking session at the 58th Annual Scientific Session of
the American College of Cardiology, held March 28-31 in Orlando, FL. Synergy is
a micro-blood pump, the size of a AA battery, that can be implanted
superficially in a “pacemaker-like” pocket. Synergy is the first and smallest
device designed for partial circulatory support (up to 3L/min) and long-term use
in patients with Class IIIb and early Class IV heart failure.
Abstract number 65205 is titled, “First Proof of Long-Term Hemodynamic Benefits
of Partial Ventricular Support in Patients with Severe Heart Failure,” and will
be presented on Monday, March 30, 2009 from 8:15-8:25am EDT. The presentation
will take place in Hall A2 of the Orange County Convention Center as part of
session number 407, Late-Breaking Clinical Trials III – Emerging Technologies.
The Company is also participating in a Texas Heart Institute satellite symposium
focused on mechanical support. This symposium, titled, “Heart Failure: Surgical
and Interventional Breakthroughs in Current Practice,” will take place on
Saturday, March 28, 2009 from 8:00am – 12:00pm at The Peabody Hotel in Orlando,
FL .
About Synergy®
The Synergy® Pocket Micro-pump represents a new approach to mechanical
circulatory support that can transform chronic heart failure management by
providing a less-invasive, elective treatment option for patients before their
disease state becomes emergent. Synergy is the first implantable system designed
to provide partial circulatory support (PCS) for long-term use in millions of
unserved patients that have NYHA Class IIIb/early IV disease.
CircuLite’s patented micro-pump provides up to 3L/min of flow, which increases
total cardiac output, offloads the heart, allowing it to rest, and potentially
enables beneficial recovery of heart function. The size of a AA battery, the
device is small enough to be implanted subcutaneously in a “pacemaker-like”
pocket through a minimally-invasive procedure.
About CircuLite®
CircuLite is transforming heart failure treatment with the development of
minimally-invasive devices for long-term partial circulatory support (PCS). By
enabling a proactive and lower-risk treatment approach by supplementing a
patient’s native pumping capacity, CircuLite has the potential to improve the
quality of life for millions of chronic heart failure patients and their
families. CircuLite’s pipeline of PCS devices is lead by the Synergy® Pocket
Micro-pump, the world’s smallest implantable blood pump currently in a CE Mark
clinical trial. Next-generation Synergy micro-pumps include an endovascular
system, a fully-implantable system and a pediatric system. For more information
on CircuLite and the Synergy Pocket Micro-pump devices, visit our website at
www.CircuLite.net.
Contact
Media:
Kari Watson or Jennifer Conrad
MacDougall Biomedical Communications
kwatson@macbiocom.com
jconrad@macbiocom.com
(781) 235-3060
